| Year |
Citation |
Score |
| 2020 |
Oh ST, Talpaz M, Gerds AT, Gupta V, Verstovsek S, Mesa R, Miller CB, Rivera CE, Fleischman AG, Goel S, Heaney ML, O'Connell C, Arcasoy MO, Zhang Y, Kawashima J, et al. ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial. Blood Advances. 4: 4282-4291. PMID 32915978 DOI: 10.1182/Bloodadvances.2020002662 |
0.312 |
|
| 2019 |
Grunwald MR, Kuter DJ, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Stein B, Oh ST, Colucci P, Parasuraman S, Paranagama D, Mesa R. Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. Clinical Lymphoma, Myeloma & Leukemia. PMID 32063527 DOI: 10.1016/J.Clml.2019.09.601 |
0.33 |
|
| 2019 |
Dao KT, Gotlib J, Deininger MMN, Oh ST, Cortes JE, Collins RH, Winton EF, Parker DR, Lee H, Reister A, Schultz, Savage S, Stevens, Brockett C, Subbiah N, et al. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900895. PMID 31880950 DOI: 10.1200/Jco.19.00895 |
0.332 |
|
| 2019 |
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister-Schultz A, Long N, White L, Carlos A, Henson RA, Lin C, ... ... Oh ST, et al. Genomic landscape of Neutrophilic Leukemias of Ambiguous Diagnosis. Blood. PMID 31366621 DOI: 10.1182/Blood.2019000611 |
0.306 |
|
| 2019 |
Fisher DAC, Miner CA, Engle EK, Hu H, Collins TB, Zhou A, Allen MJ, Malkova ON, Oh ST. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling. Leukemia. PMID 30718771 DOI: 10.1038/S41375-019-0379-Y |
0.304 |
|
| 2019 |
Fuh KC, Lomonosova E, Guo L, Fantl W, Pachynski RK, Malkova O, Oh ST, Hagemann AR, McCourt CK, Powell MA, Thaker PH. Identifying a potential biomarker for anti-PD-1 immunotherapy in patients with advanced stage, surgically-resectable endometrial cancer. Journal of Clinical Oncology. 37: 5590-5590. DOI: 10.1200/Jco.2019.37.15_Suppl.5590 |
0.312 |
|
| 2019 |
Wang T, Sun H, Cui Zhou D, Liu R, Yao L, Fiala MA, Kohnen DR, O'Neal J, Rettig MP, Fowles JS, Oh ST, Jayasinghe RG, Vij R, DiPersio JF, Ding L. Single-Cell Pathway Enrichment and Regulatory Profiling of Multiple Myeloma across Disease Stages Blood. 134: 364-364. DOI: 10.1182/Blood-2019-131361 |
0.321 |
|
| 2019 |
Fowles JS, Fisher DA, Zhou A, Oh ST. Altered Dynamics of Monocyte Subpopulations and Pro-Inflammatory Signaling Pathways in Polycythemia Vera Revealed By Mass Cytometry Blood. 134: 4210-4210. DOI: 10.1182/Blood-2019-131128 |
0.348 |
|
| 2019 |
Collins TB, Luff SA, Batista LF, Sturgeon CM, Oh ST. Interrogating the Role of ASXL1 and JAK2 mutations in Myeloproliferative Neoplasms Utilizing Human Pluripotent Stem Cells Blood. 134: 2971-2971. DOI: 10.1182/Blood-2019-130541 |
0.364 |
|
| 2019 |
O'Sullivan J, Taylor JA, Gerds AT, Buckley SA, Harrison CN, Oh ST, Howard K, Dreau HM, Hamblin A, Mead AJ. Molecular Analysis in the Pacritinib Dose-Finding PAC203 Study in Patients with Myelofibrosis Refractory or Intolerant to Ruxolitinib Blood. 134: 4214-4214. DOI: 10.1182/Blood-2019-129254 |
0.376 |
|
| 2019 |
Schriefer RE, Arguelles GR, Mitchell LM, Oh ST, Atkinson JP, Hourcade DE, Kim AH. 147 Characterization of cell-bound complement activation products on SLE PBMCs using mass cytometry Lupus Science & Medicine. 6. DOI: 10.1136/Lupus-2019-Lsm.147 |
0.31 |
|
| 2018 |
Celik H, Koh WK, Kramer AC, Ostrander EL, Mallaney C, Fisher DAC, Xiang J, Wilson WC, Martens A, Kothari A, Fishberger G, Tycksen E, Karpova D, Duncavage EJ, Lee Y, ... Oh ST, et al. JARID2 Functions as a Tumor Suppressor in Myeloid Neoplasms by Repressing Self-Renewal in Hematopoietic Progenitor Cells. Cancer Cell. 34: 741-756.e8. PMID 30423295 DOI: 10.1016/J.Ccell.2018.10.008 |
0.313 |
|
| 2018 |
Spiciarich DR, Oh ST, Foley A, Hughes SB, Mauro MJ, Abdel-Wahab O, Press RD, Viner R, Thompson SL, Chen Q, Azadi P, Bertozzi CR, Maxson JE. A novel germline variant in CSF3R reduces N-glycosylation and exerts potent oncogenic effects in leukemia. Cancer Research. PMID 30348809 DOI: 10.1158/0008-5472.Can-18-1638 |
0.308 |
|
| 2018 |
Mesa R, Boccia RV, Grunwald MR, Oh ST, Colucci P, Paranagama D, Parasuraman S, Stein BL. Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clinical Lymphoma, Myeloma & Leukemia. 18: 590-596. PMID 30122202 DOI: 10.1016/J.Clml.2018.05.020 |
0.3 |
|
| 2018 |
Throm AA, Moncrieffe H, Orandi AB, Pingel JT, Geurs TL, Miller HL, Daugherty AL, Malkova ON, Lovell DJ, Thompson SD, Grom AA, Cooper MA, Oh ST, French AR. Identification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry. Jci Insight. 3. PMID 30089725 DOI: 10.1172/Jci.Insight.121544 |
0.327 |
|
| 2018 |
Dao K, Collins RH, Cortes JE, Deininger MW, Druker BJ, Gotlib JR, Macey TA, Oh ST, Tyner JW, Winton EF. Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia Blood. 132: 350-350. DOI: 10.1182/Blood-2018-99-119476 |
0.335 |
|
| 2018 |
Fisher DA, Miner C, Engle E, Hu H, Collins TB, Zhou A, Allen MJ, Malkova O, Oh ST. Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling Blood. 132: 3062-3062. DOI: 10.1182/Blood-2018-99-119022 |
0.322 |
|
| 2017 |
Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, et al. Myeloid/lymphoid neoplasms with FGFR1 rearrangement. Leukemia & Lymphoma. 1-5. PMID 29119847 DOI: 10.1080/10428194.2017.1397663 |
0.335 |
|
| 2017 |
Bandyopadhyay S, Li J, Traer E, Tyner JW, Zhou A, Oh ST, Cheng JX. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. Plos One. 12: e0179558. PMID 28719608 DOI: 10.1371/Journal.Pone.0179558 |
0.36 |
|
| 2017 |
How J, Zhou A, Oh ST. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease. Therapeutic Advances in Hematology. 8: 107-118. PMID 28246554 DOI: 10.1177/2040620716680333 |
0.35 |
|
| 2017 |
Grunwald MR, Altomare I, Burke JM, Gerds AT, Walshauser MA, Savona MR, Kuter DJ, Stein BL, Oh S, Colucci P, Naim AB, Paranagama DC, Mesa RA. Examining the Treatment Patterns and Blood Counts Among Patients with Polycythemia Vera Treated with Hydroxyurea in the United States: An Analysis from the Reveal Study Blood. 130: 1633-1633. DOI: 10.1182/Blood.V130.Suppl_1.1633.1633 |
0.311 |
|
| 2016 |
Fisher DA, Malkova O, Engle EK, Miner C, Fulbright MC, Behbehani GK, Collins TB, Bandyopadhyay S, Zhou A, Nolan GP, Oh ST. Mass cytometry analysis reveals hyperactive NF Kappa B signaling in myelofibrosis and secondary acute myeloid leukemia. Leukemia. PMID 28008177 DOI: 10.1038/Leu.2016.377 |
0.386 |
|
| 2016 |
Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, ... ... Oh ST, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The New England Journal of Medicine. 375: 2023-2036. PMID 27959731 DOI: 10.1056/Nejmoa1605949 |
0.384 |
|
| 2016 |
Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, et al. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1572-1611. PMID 27956542 DOI: 10.6004/Jnccn.2016.0169 |
0.351 |
|
| 2016 |
Rashidi A, Heusel JW, Oh ST. Concurrent MPL W515L and Y591D mutations in a patient with myelofibrosis. Blood Cells, Molecules & Diseases. 60: 1-2. PMID 27519934 DOI: 10.1016/J.Bcmd.2016.05.010 |
0.344 |
|
| 2016 |
Oh ST, Miller CA, Gindin Y, Brost TM, Chan J, Fulbright MC, Fisher DA, Duncavage EJ, O'Laughlin M, Griffith M, Griffith OL, Wartman LD. Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia Blood. 128: 5496-5496. DOI: 10.1182/Blood.V128.22.5496.5496 |
0.401 |
|
| 2016 |
Fisher DA, Miner CA, Engle EK, Brost TM, Malkova O, Oh ST. Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis Blood. 128: 4277-4277. DOI: 10.1182/Blood.V128.22.4277.4277 |
0.367 |
|
| 2016 |
Hughes SB, Spiciarich D, Press RD, Thompson SL, Radich JP, Bertozzi C, Oh ST, Maxson JE. A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation Blood. 128: 3141-3141. DOI: 10.1182/Blood.V128.22.3141.3141 |
0.375 |
|
| 2016 |
How J, Oh ST, Trinkaus KM. Distinct Clinical, Laboratory, and Molecular Features of Myeloproliferative Neoplasm Patients Presenting with Splanchnic Vein Thrombosis Blood. 128: 3121-3121. DOI: 10.1182/Blood.V128.22.3121.3121 |
0.362 |
|
| 2016 |
Stein BL, Naim A, Grunwald MR, Moliterno AR, Oh ST, Paranagama D, Cordaro JA, Sun H, Parasuraman S, Boccia RV, Mesa R. Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study Blood. 128: 1934-1934. DOI: 10.1182/Blood.V128.22.1934.1934 |
0.337 |
|
| 2015 |
Zhou A, Knoche EM, Engle EK, Fisher DA, Oh ST. Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer Journal. 5: e351. PMID 26430722 DOI: 10.1182/Blood.V120.21.2832.2832 |
0.346 |
|
| 2015 |
Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, et al. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26324368 DOI: 10.1200/Jco.2015.61.6474 |
0.341 |
|
| 2015 |
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, ... ... Oh ST, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. Journal of the National Comprehensive Cancer Network : Jnccn. 13: 424-34. PMID 25870379 DOI: 10.6004/Jnccn.2015.0058 |
0.323 |
|
| 2015 |
Engle EK, Fisher DA, Miller CA, McLellan MD, Fulton RS, Moore DM, Wilson RK, Ley TJ, Oh ST. Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. Leukemia. 29: 869-76. PMID 25252869 DOI: 10.1182/Blood.V120.21.706.706 |
0.331 |
|
| 2015 |
Gupta V, Baer MR, Oh ST, Miller CB, Jun S, Lee P, Dong H, Reiter A. Phase III randomized, open-label, active-controlled study of momelotinib versus best available therapy in ruxolitinib-treated patients with myelofibrosis. Journal of Clinical Oncology. 33: TPS7102-TPS7102. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps7102 |
0.34 |
|
| 2015 |
Winton EF, Devos T, Oh ST, Platzbecker U, Wadleigh M, Jun S, Lee P, Deng W, Gupta V. Phase III randomized, double-blind, active-controlled study of momelotinib versus ruxolitinib in patients with myelofibrosis. Journal of Clinical Oncology. 33: TPS7101-TPS7101. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps7101 |
0.309 |
|
| 2015 |
Welch JS, Petti A, Miller CA, Link DC, Walter MJ, Fronick CC, Fulton RS, Wartman LD, Uy GL, Ghobadi A, Tomasson M, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein K, ... ... Oh S, et al. Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients Blood. 126: 689-689. DOI: 10.1182/Blood.V126.23.689.689 |
0.379 |
|
| 2015 |
Fisher DA, Engle EK, Malkova O, Fulbright MC, Zhou A, Oh S. NF Kappa B Signaling Hyperactivation in Myelofibrosis and Secondary Acute Myeloid Leukemia Blood. 126: 602-602. DOI: 10.1182/Blood.V126.23.602.602 |
0.37 |
|
| 2014 |
Zhou A, Oh ST. Prognostication in MF: from CBC to cytogenetics to molecular markers. Best Practice & Research. Clinical Haematology. 27: 155-64. PMID 25189726 DOI: 10.1016/J.Beha.2014.07.008 |
0.328 |
|
| 2014 |
Yano M, Imamura T, Sakamoto K, Asai D, Kano G, Hosoi H, Deguchi T, Hashii Y, Endo M, Sato A, Kawasaki H, Kosaka Y, Kato K, Hori H, Yumura K, ... ... Oh ST, et al. Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia Blood. 124: 3772-3772. DOI: 10.1182/Blood.V124.21.3772.3772 |
0.398 |
|
| 2014 |
Fisher DA, Malkova O, Fulbright MC, Behbehani GK, Nolan GP, Oh ST. Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms Blood. 124: 1884-1884. DOI: 10.1182/Blood.V124.21.1884.1884 |
0.335 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Pond JB, Collins RH, Goueli B, Oh ST, Deininger MW, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. The New England Journal of Medicine. 368: 1781-90. PMID 23656643 DOI: 10.1056/Nejmoa1214514 |
0.31 |
|
| 2013 |
Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB, Bryant J, Glover JM, Chang BH, Spurgeon SE, Fleming WH, Kovacsovics T, Gotlib JR, Oh ST, Deininger MW, Zwaan CM, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Research. 73: 285-96. PMID 23087056 DOI: 10.1158/0008-5472.Can-12-1906 |
0.312 |
|
| 2013 |
Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Luty SB, Abel M, Eide CA, Bottomly D, Wilmot B, McWeeney SK, Tognon CE, Collins RH, Pond JB, Goueli B, ... Oh ST, et al. The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization Blood. 122: 270-270. DOI: 10.1182/Blood.V122.21.270.270 |
0.369 |
|
| 2013 |
Fisher DA, Behbehani GK, Nolan GP, Bendall SC, Oh ST. Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib Blood. 122: 1610-1610. DOI: 10.1182/Blood.V122.21.1610.1610 |
0.39 |
|
| 2012 |
Schmidt AE, Oh ST. Pathology consultation on myeloproliferative neoplasms. American Journal of Clinical Pathology. 138: 12-9. PMID 22706852 DOI: 10.1309/Ajcplriojp55Jayt |
0.323 |
|
| 2012 |
Fisher DA, Simonds EF, Behbehani GK, Nolan GP, Bendall SC, Oh ST. Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia Blood. 120: 703-703. DOI: 10.1182/Blood.V120.21.703.703 |
0.364 |
|
| 2011 |
Oh ST. When the Brakes are Lost: LNK Dysfunction in Mice, Men, and Myeloproliferative Neoplasms. Therapeutic Advances in Hematology. 2: 11-9. PMID 23556072 DOI: 10.1177/2040620710393391 |
0.36 |
|
| 2010 |
Oh ST, Gotlib J. JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms. Expert Review of Hematology. 3: 323-37. PMID 21082983 DOI: 10.1586/Ehm.10.28 |
0.394 |
|
| 2010 |
Pardanani A, Lasho T, Finke C, Oh ST, Gotlib J, Tefferi A. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations. Leukemia. 24: 1713-8. PMID 20724988 DOI: 10.1038/Leu.2010.163 |
0.335 |
|
| 2010 |
Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, Merker JD, Zehnder JL, Nolan GP, Gotlib J. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 116: 988-92. PMID 20404132 DOI: 10.1182/Blood-2010-02-270108 |
0.388 |
|
| 2010 |
Merker JD, Jones CD, Oh ST, Schrijver I, Gotlib J, Zehnder JL. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory. The Journal of Molecular Diagnostics : Jmd. 12: 58-64. PMID 19959796 DOI: 10.2353/Jmoldx.2010.090068 |
0.343 |
|
| 2010 |
Oh ST, Zahn JM, Jones CD, Zhang B, Loh ML, Kantarjian H, Simonds EF, Bruggner RV, Abidi P, Natsoulis G, Bell J, Buenrostro J, Nolan GP, Zehnder JL, Ji HP, et al. Identification of Novel LNK Mutations In Patients with Chronic Myeloproliferative Neoplasms and Related Disorders Blood. 116: 315-315. DOI: 10.1182/Blood.V116.21.315.315 |
0.396 |
|
| 2010 |
Gotlib J, Zhang B, Jones CD, Riess J, Wong WB, Simonds EF, Hale MB, Abidi P, McClung J, Nolan GP, Oh ST, Zehnder JL. Identification of a Novel Splice Donor Mutation In the Thrombopoietin Gene In a Philippine Family with Hereditary Thrombocythemia Blood. 116: 3086-3086. DOI: 10.1182/Blood.V116.21.3086.3086 |
0.332 |
|
| 2010 |
Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD, Merker JD, Zehnder JL, Nolan GP, Gotlib J. Abstract 239: Mutation of the inhibitory adaptor protein LNK drives potentiated JAK-STAT signaling in patients with JAK2 V617F-negative myeloproliferative neoplasms Cancer Research. 70: 239-239. DOI: 10.1158/1538-7445.Am10-239 |
0.399 |
|
| 2010 |
Oh ST, Zahn JM, Simonds EF, Bell J, Natsoulis G, Buenstro J, Jones C, Hale MB, Goltsev Y, Gibbs KD, Merker JD, Zehnder JL, Davis RW, Nolan GP, Ji HP, et al. Abstract B6: Identification of novel mutations in the inhibitory adaptor protein LNK in patients with JAK2 V617F-negative and -positive chronic myeloproliferative neoplasms Clinical Cancer Research. 16. DOI: 10.1158/1078-0432.Tcmusa10-B6 |
0.396 |
|
| 2009 |
Tyner JW, Fletcher L, Yang W, Oh ST, Gotlib JR, Deininger MW, Druker BJ, Loriaux M. Development of a Small-Molecule Inhibitor Screen to Rapidly Identify Key Signaling Pathways in Leukemogenesis. Blood. 114: 708-708. DOI: 10.1182/Blood.V114.22.708.708 |
0.33 |
|
| 2009 |
Tyner JW, Loriaux M, Willis SG, Chang BH, Bicocca VT, Oh ST, Hollink IH, Segers S, DenBoer ML, van den Heuvel-Eibrink MM, Zwaan CM, Gotlib JR, Deininger M, Druker BJ. RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies. Blood. 114: 3978-3978. DOI: 10.1182/Blood.V114.22.3978.3978 |
0.328 |
|
| 2004 |
Oh ST, Longworth MS, Laimins LA. Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. Journal of Virology. 78: 2620-6. PMID 14963169 DOI: 10.1128/Jvi.78.5.2620-2626.2004 |
0.691 |
|
| 2001 |
Thomas JT, Oh ST, Terhune SS, Laimins LA. Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. Journal of Virology. 75: 7564-71. PMID 11462028 DOI: 10.1128/Jvi.75.16.7564-7571.2001 |
0.668 |
|
| 2001 |
Oh ST, Kyo S, Laimins LA. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. Journal of Virology. 75: 5559-66. PMID 11356963 DOI: 10.1128/Jvi.75.12.5559-5566.2001 |
0.565 |
|
| Show low-probability matches. |